Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma

Background Many patients with severe asthma rely on oral glucocorticoids to manage their disease. We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocorticoid-sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated with eosinophilia. Methods In a 28-week randomized, controlled trial, we assessed the effects of benralizumab (at a dose of 30 mg administered subcutaneously either every 4 weeks or every 8 weeks [with the first three doses administered every 4 weeks]) versus placebo on the reduction in the oral glucocorticoid dose while asthma control was maintained in adult patients with severe asthma. The primary end point was the percentage change in the oral glucocorticoid dose from baseline to week 28. Annual asthma exacerbation rates, lung function, symptoms, and safety were assessed. Results Of 369 patients enrolled, 220 underwent randomization and started receiving benralizumab or placebo. The two benralizumab dosing regimens significantly reduced the median final oral glucocorticoid doses from baseline by 75%, as compared with a reduction of 25% in the oral glucocorticoid doses in the placebo group (P<0.001 for both comparisons). The odds of a reduction in the oral glucocorticoid dose were more than 4 times as high with benralizumab as with placebo. Among the secondary outcomes, benralizumab administered every 4 weeks resulted in an annual exacerbation rate that was 55% lower than the rate with placebo (marginal rate, 0.83 vs. 1.83, P=0.003), and benralizumab administered every 8 weeks resulted in an annual exacerbation rate that was 70% lower than the rate with placebo (marginal rate, 0.54 vs. 1.83, P<0.001). At 28 weeks, there was no significant effect of either benralizumab regimen on the forced expiratory volume in 1 second (FEV1), as compared with placebo. The effects on various measures of asthma symptoms were mixed, with some showing significant changes in favor of benralizumab and others not showing significant changes. Frequencies of adverse events were similar between each benralizumab group and the placebo group. Conclusions Benralizumab showed significant, clinically relevant benefits, as compared with placebo, on oral glucocorticoid use and exacerbation rates. These effects occurred without a sustained effect on the FEV1. (Funded by AstraZeneca; ZONDA ClinicalTrials.gov number, NCT02075255.).

Medienart:	Artikel

Erscheinungsjahr:	2017
Erschienen:	2017

Enthalten in:	Zur Gesamtaufnahme - volume:376
Enthalten in:	The New England journal of medicine - 376(2017), 25, Seite 2448

Sprache:	Englisch

Beteiligte Personen:	Parameswaran Nair [VerfasserIn] Sally Wenzel [Sonstige Person] Klaus F Rabe [Sonstige Person] Arnaud Bourdin [Sonstige Person] Njira L Lugogo [Sonstige Person] Piotr Kuna [Sonstige Person] Peter Barker [Sonstige Person] Stephanie Sproule [Sonstige Person] Sandhia Ponnarambil [Sonstige Person] Mitchell Goldman [Sonstige Person]

Links:	search.proquest.com

BKL:	44.60 44.00
Themen:	Allografts Asthma Clinical trials Cytokines Drug therapy Eosinophilia Glucocorticoids Interleukin 5 Lung Monoclonal antibodies Oral cavity

RVK:	RVK Klassifikation XA 10000

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC1995100919